Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016.
June 29, 2026 07:15 AM EDT
DealsPharma
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
Ayisha Sharma
News Reporter
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a…
Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.
Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.
Cartesian’s $150M financing; Editas Medicine’s money moves
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion…
Kardigan launches $320M IPO to fund three late-stage cardio drugs as biotech listings hit a post-pandemic high.
